Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
China · Delayed Price · Currency is CNY 29.83
-0.93 (-3.02%)
Sep 10, 2026, 2:45 PM CST
SHE:300584 Revenue
Nanjing Hicin Pharmaceutical had revenue of 203.81M CNY in the quarter ending June 30, 2026, with 22.84% growth. This brings the company's revenue in the last twelve months to 726.62M, up 26.06% year-over-year. In the year 2025, Nanjing Hicin Pharmaceutical had annual revenue of 671.05M with 33.05% growth.
Revenue (ttm)
726.62M
Revenue Growth
+26.06%
P/S Ratio
5.08
Revenue / Employee
1.31M
Employees
553
Market Cap
3.69B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 671.05M | 166.69M | 33.05% |
| Dec 31, 2024 | 504.36M | -13.47M | -2.60% |
| Dec 31, 2023 | 517.83M | -8.63M | -1.64% |
| Jan 1, 2023 | 526.47M | -51.85M | -8.97% |
| Jan 1, 2022 | 578.32M | -127.98M | -18.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Starry Pharmaceutical | 2.46B |
| Nanjing Well Pharmaceutical Group | 1.40B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Harbin Medisan Pharmaceutical | 805.09M |
| Newland Pharmaceutical | 710.55M |
| Shaanxi Kanghui Pharmaceutical | 429.09M |
| Lionco Pharmaceutical Group | 408.33M |
| Hainan Shuangcheng Pharmaceuticals | 309.80M |